Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Malaria Vaccines
New malaria vaccines study findings recently were reported by investigators at Johns Hopkins University, Johns Hopkins Malaria Research Institute
March 19th, 2008
Research findings, 'Markedly enhanced immunogenicity of a Pfs25 DNA-based malaria transmission-blocking vaccine by in vivo electroporation,' are discussed in a new report. According to a study from the United States, "Pfs25 is a promising target antigen for the development of a malaria transmission-blocking vaccine and prior research has demonstrated induction of high and functionally effective antibodies in mice with IM injection of Pfs25 encoding DNA plasmid. Likewise, Pfs25 DNA vaccine was immunogenic in rhesus macaques but required a protein boost to elicit significant transmission-blocking antibodies." "The translation of these encouraging findings to human...
Source: Vaccine Weekly (2008-03-19)
|
